公开(公告)号：US20230399384A1

公开(公告)日：2023-12-14

申请号：US17996874

申请日：2021-04-22

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Zhiqiang KU ,  Ningyan ZHANG ,  Zhiqiang AN ,  Xuping XIE ,  Pei-Yong SHI

IPC: C07K16/10 ,  A61P31/14

CPC classification number: C07K16/1003 ,  A61P31/14 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/34 ,  A61K2039/505

Abstract: Provided herein are antibodies binding to Coronavirus S protein and the uses of the antibodies in detecting and treating Coronavirus infection, such as COVID-19.

公开(公告)号：US20230348586A1

公开(公告)日：2023-11-02

申请号：US18026696

申请日：2021-09-21

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Phillipp E. SCHERER ,  Shangang ZHAO ,  Zhiqiang AN ,  Ningyan ZHANG

IPC: C07K16/26 ,  A61K38/46 ,  A61K31/7088 ,  A61K38/22 ,  C12N15/113 ,  A61K38/26 ,  A61K39/395 ,  A61P3/04 ,  A61P35/02 ,  A61P35/00 ,  A61P9/00 ,  A61P1/16

CPC classification number: C07K16/26 ,  A61K38/465 ,  A61K31/7088 ,  A61K38/2264 ,  C12N15/1136 ,  A61K38/26 ,  A61K39/3955 ,  A61P3/04 ,  A61P35/02 ,  A61P35/00 ,  A61P9/00 ,  A61P1/16 ,  C12N2310/14 ,  C12N2310/531 ,  A61K2039/505

Abstract: The present disclosure relates generally to therapeutic agents and related uses thereof, including, agents for reducing leptin in a patient or subject and methods of treatment thereof. The therapeutic agents can comprise (without limitation), an antibody or specific binding fragment thereof, a leptin antagonist, a leptin targeting antisense oligonucleotide, a leptin targeting small interfering RNA (siRNA), a leptin targeting short hairpin RNA (shRNA), and/or a gene editing composition directed to at least one target sequence of a leptin polynucleotide. The therapeutic agents can be used in various methods of treatment, including (without limitation), treating liver fibrosis, cancer, inducing or maintaining weight loss, reducing or preventing weight gain, and increasing insulin sensitivity, among others.

公开(公告)号：US20210179687A1

公开(公告)日：2021-06-17

申请号：US16762273

申请日：2018-11-06

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Chengcheng ZHANG ,  Samuel JOHN ,  Heyu CHEN ,  Mi DENG ,  Xun GUI ,  Ningyan ZHANG ,  Zhiqiang AN

IPC: C07K14/705 ,  A61K45/06 ,  A61P35/02 ,  C12N5/0783

Abstract: The present disclosure provides methods and compositions for immunotherapy employing a modified T cell or NK cell comprising a chimeric LILRB4 antigen receptor (CAR) that can be administered to patients for disease (e.g., cancer) treatment.

公开(公告)号：US20190031751A1

公开(公告)日：2019-01-31

申请号：US16075711

申请日：2017-02-06

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Ningyan ZHANG ,  Zhiqiang AN ,  Anil K. SOOD

IPC: C07K16/22 ,  A61P35/00 ,  A61K9/00 ,  C12N15/113

Abstract: Isolated or recombinant anti-EGFL6 monoclonal antibodies are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer.

公开(公告)号：US20240376222A1

公开(公告)日：2024-11-14

申请号：US18691125

申请日：2022-09-13

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Zhiqiang AN ,  Ningyan ZHANG ,  Peng ZHAO

IPC: C07K16/28 ,  A61K49/00 ,  C07K14/725

Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a TfR protein, e.g., a mammalian TfR or human TfR, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

公开(公告)号：US20230235078A1

公开(公告)日：2023-07-27

申请号：US18176072

申请日：2023-02-28

Applicant: The BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM ,  THE GEORGE WASHINGTON UNIVERSITY

Inventor： Ningyan ZHANG ,  Zhiqiang AN ,  Hui DENG ,  Xiujie SUN ,  Rong LI

IPC: C07K16/28 ,  C12N15/63 ,  A61P35/00

CPC classification number: C07K16/2896 ,  C12N15/63 ,  A61P35/00 ,  C07K2317/20 ,  C07K2317/565

Abstract: The present disclosure relates to antibodies binding to tumor discoidin domain receptor 1 (DDR1) and the uses of the antibodies in detecting and treating cancer.

公开(公告)号：US20210349096A1

公开(公告)日：2021-11-11

申请号：US16321745

申请日：2017-07-27

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Chengcheng ZHANG ,  Zhiqiang AN ,  Ningyan ZHANG ,  Mi DENG ,  Jaehyup KIM ,  Xun GUI

IPC: G01N33/574 ,  G01N33/50 ,  G01N15/14 ,  G01N21/64

Abstract: Provided herein are methods and compositions for the identification of modulators of ApoE-induced LILRB activation. Also provided herein are methods of treating cancer comprising the administration of an inhibitor of ApoE-induced LILRB activation. Also provided are methods of treating autoimmune disease or inhibiting the onset of transplant rejection or treating an inflammatory disorder comprising administering an agonist of ApoE-induced LILRB activation to a subject.

公开(公告)号：US20230068663A1

公开(公告)日：2023-03-02

申请号：US17759800

申请日：2021-01-28

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM ,  IMMUNE-ONC THERAPEUTICS, INC.

Inventor： Zhiqiang AN ,  Ningyan ZHANG ,  Zhiqiang KU ,  Chengcheng ZHANG ,  Xiaoye XU ,  Heyu CHEN ,  JingJing XIE ,  Maria Jose COSTA ,  An SONG ,  X. Charlene LIAO

IPC: C07K16/28 ,  A61K45/06 ,  A61K47/68 ,  A61P35/02 ,  A61K39/395 ,  G01N33/574

Abstract: Provided herein are antibodies binding to LILRB2 and the uses of the antibodies in detecting and treating cancer and autoimmune diseases.

公开(公告)号：US20210371518A1

公开(公告)日：2021-12-02

申请号：US17275838

申请日：2019-09-12

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM ,  IMMUNE-ONC THERAPEUTICS, INC.

Inventor： Zhiqiang AN ,  Chengcheng ZHANG ,  Ningyan ZHANG ,  Xun GUI ,  Mi DENG ,  Tao HUANG ,  Qiang LIU ,  X. Charlene LIAO

IPC: C07K16/28 ,  A61P35/02 ,  A61K45/06 ,  A61K39/395 ,  A61K47/68 ,  A61K51/10 ,  G01N33/574 ,  A61K47/69

Abstract: The present disclosure provides an isolated monoclonal antibody or an antigen-binding fragment thereof that binds specifically to leukocyte immunoglobulin-like receptor 4 (LILRB4). In certain embodiments, the antibody or antigen-binding fragment, when bound to LILRB4, modulates the activation of LILRB4. In certain embodiments, the antibody or antigen-binding fragment, when bound to LILRB4, activates LILRB4. In certain embodiments, the antibody or antigen binding fragment, when bound to LILRB4, suppresses activation of LILRB4. In certain embodiments, the antibody or antigen-binding fragment, when bound to LILRB4, specifically blocks binding of ApoE to LILRB4. In another aspect, there is provided a method of treating or ameliorating the effects of a cancer in a subject, comprising administering to the subject a therapeutically effective amount of the antibody or an antigen-binding fragment thereof or an engineered cell as provided herein.

公开(公告)号：US20210130450A1

公开(公告)日：2021-05-06

申请号：US17096280

申请日：2020-11-12

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Ningyan ZHANG ,  Zhiqiang AN ,  Anil K. SOOD

IPC: C07K16/22 ,  C12N15/113 ,  G01N33/574 ,  A61P35/00 ,  A61K9/00

Abstract: Isolated or recombinant anti-EGFL6 monoclonal antibodies are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer.